Trial Profile
Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Thyroid cancer
- Focus Therapeutic Use
- Acronyms RAD-THYR; RADTHYR
- 01 Sep 2021 Primary endpoint (Metabolic response (PERCIST criteria)) has not been met, as per results published in the European Journal of Nuclear Medicine and Molecular Imaging.
- 01 Sep 2021 Status changed from completed to discontinued, as per results published in the European Journal of Nuclear Medicine and Molecular Imaging.
- 01 Sep 2021 Results assessing efficacy and the tolerance of alpha emitter Radium-223 in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) differentiated thyroid cancer, published in the European Journal of Nuclear Medicine and Molecular Imaging.